Search results
AbTherx Opens Antibody Discovery Technologies Research Center
Digital Journal· 7 hours ago"I'm excited to unlock the full potential of our Atlas™ Mice platform with these new automated capabilities in advanced hybridoma, single B cell screening ...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 1 day agoAlthough several targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors and B cell...
A cure for multiple sclerosis? Scientists say within our lifetime
UC Newsroom· 5 days agoPeople diagnosed today can live a long life free of disability, as UCSF research ushers in a golden...
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with...
Benzinga· 2 days agoDr. Kim Linton, M.B.Ch.B, MRCP, Ph.D., FRCP, senior lecturer at the University of Manchester...
Blincyto Picks Up New BCP-ALL Indication
Medscape· 12 hours agoThe agent is the first BiTE approved for consolidation regardless of MRD status.
Is 'Difficult-to-Treat' RA a Lost Cause?
MedPage Today· 6 days agoRheumatologists are still struggling with what to do when multiple state-of-the-art treatments have failed to bring rheumatoid arthritis (RA) under...
Health Care Roundup: Market Talk
The Wall Street Journal· 20 hours agoNEWSPLUS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1054 ET...
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? - Nurix Therapeutics...
Benzinga· 1 day agoImbruvica (Ibrutinib), and AstraZeneca Plc’s AZN Calquence (Acalabrutinib). NX-5948 is being...
Biotech With 345% Run Posts A 'Clear Win' In Cancer Treatment
Investor's Business Daily· 21 hours agoThe company tested its treatment, dubbed NX-5948, in patients with relapsed or refractory forms of...
Roche shares hold as analyst backs Buy rating By Investing.com
Investing.com· 1 day agoThe data presented was the first of its kind for one of Roche's CD20 bispecifics, indicating a...
